Company: DMAAR
Filing Date: 2025-11-18
Form Type: 10-Q
Source: 0001213900-25-112096
Chunk: 25

Company: Drugs Made In America Acquisition Corp.
Filing Date: 2025-11-18
Form: 10-Q
Item: Part I, Item 1
Chunk 25
---
324, respectively, outstanding under the Promissory Note.

Advisory
Services

The
Company received advisory services from an uncompensated related party advisor, husband to the CEO of the Company (the “Advisor”).
The role of such advisor is to assist in the day-to-day transactions of the Company.

CFO
Agreement

Effective
July 1, 2024, the Company’s CFO has a consulting agreement with the Company. For the three and nine months ended September 30,
2025, the Company has incurred $8,825 and $22,764 of expense reported in general and administrative costs on the unaudited statement
of operations, respectively. As of September 30, 2025 and December 30, 2024, $20,000 and $0, respectively, was paid to the Advisor.
As of September 30, 2025 and December 31, 2024, $0 and $1,300 is included in accounts payable and accrued expenses on the balance
sheets.

Related
Party Loans

In
order to finance transaction costs in connection with a Business Combination, the Sponsor or an affiliate of the Sponsor, or certain
of the Company’s officers and directors may, but are not obligated to, loan the Company funds as may be required (“Working
Capital Loans”). If the Company completes a Business Combination, the Company would repay the Working Capital Loans out of the
proceeds of the Trust Account released to the Company. Otherwise, the Working Capital Loans would be repaid only out of funds held outside
the Trust Account. In the event that a Business Combination does not close, the Company may use a portion of proceeds held outside the
Trust Account to repay the Working Capital Loans, but no proceeds held in the Trust Account would be used to repay the Working Capital
Loans. Except for the foregoing, the terms of such Working Capital Loans, if any, have not been determined and no written agreements
exist with respect to such loans. The Working Capital Loans would either be repaid upon consummation of a Business Combination, without
interest, or, at the lender’s discretion, up to $1,500,000 of such Working Capital Loans may be convertible into units of the post-Business
Combination entity at a price of $10.00 per unit. The units would be identical to the Private Placement Units. As of September 30, 2025
and December 31, 2024, no working capital loans were